These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1789 related items for PubMed ID: 8631191

  • 1. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
    Heikinheimo O, Gordon K, Williams RF, Hodgen GD.
    Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
    [Abstract] [Full Text] [Related]

  • 2. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R, Alfthan H, Haukkamaa M, Heikinheimo O, Luukkainen T, Lähteenmäki P.
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [Abstract] [Full Text] [Related]

  • 3. Antiovulatory actions of RU 486: the pituitary is not the primary site of action in vivo.
    Heikinheimo O, Gordon K, Lähteenmäki P, Williams RF, Hodgen GD.
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1859-68. PubMed ID: 7775633
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B, Zeng T, Wu S, Sun H, Xiao N.
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [Abstract] [Full Text] [Related]

  • 6. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R, Messinis LE, Fowler P, Groome NP, Knight PG, Templeton AA.
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [Abstract] [Full Text] [Related]

  • 7. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
    Liu JH, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen SS.
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
    Luukkainen T, Heikinheimo O, Haukkamaa M, Lähteenmäki P.
    Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
    [Abstract] [Full Text] [Related]

  • 9. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG, Liu J, Ulmann A, Baulieu E, Yen SS.
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [Abstract] [Full Text] [Related]

  • 10. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
    Katkam RR, Gopalkrishnan K, Chwalisz K, Schillinger E, Puri CP.
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
    [Abstract] [Full Text] [Related]

  • 11. Response to intermittent RU486 in women.
    Spitz IM, Croxatto HB, Salvatierra AM, Heikinheimo O.
    Fertil Steril; 1993 May; 59(5):971-5. PubMed ID: 8486197
    [Abstract] [Full Text] [Related]

  • 12. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
    Cameron ST, Thong KJ, Baird DT.
    Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
    [Abstract] [Full Text] [Related]

  • 13. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
    Greene KE, Kettel LM, Yen SS.
    Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
    [Abstract] [Full Text] [Related]

  • 14. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
    Letterie GS.
    Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
    [Abstract] [Full Text] [Related]

  • 15. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB, Massai MR, Salvatierra AM, Fuentealba B, Croxatto HD, Lähteenmäki P.
    Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
    [Abstract] [Full Text] [Related]

  • 16. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
    Alvarez F, Brache V, Faundes A, Tejada AS, Thevenin F.
    Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM, Segal S, Salem HT, Ghaneimah SA, Khalifa EA, Ahmed AG.
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M, Haukkamaa M, Lähteenmäki P.
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 90.